Stock Market Reviews

Read and share opinions on ONCY (Oncolytics Biotech Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care
  Oct 28, 2025
• Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada
  Oct 20, 2025
• Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
  Sep 29, 2025
• Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion
  Sep 16, 2025
• Oncolytics Says Pelareorep Drug Shows 'Strong Efficacy, Translational Data' in Metastatic Colorectal Cancer
  Sep 8, 2025
• Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions
  Sep 8, 2025
• Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors
  Sep 2, 2025
• Oncolytics Biotech® Announces Upcoming Investor Conferences in September
  Aug 28, 2025
• Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
  Aug 11, 2025
• Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
  Aug 8, 2025
• Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange
  Aug 8, 2025
• Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
  Aug 5, 2025
• Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End
  Jul 29, 2025
• Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
  Jul 23, 2025
• Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
  Jul 22, 2025
• Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types
  Jul 16, 2025